Quick Answer
Roivant Sciences Ltd. reported Long-Term Debt of $430.59 million for fiscal year 2024.
Roivant Sciences Ltd. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $430.59M | +14.7% |
| 2023 | $375.51M | +78.8% |
| 2022 | $210.03M | +23.3% |
| 2021 | $170.28M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | $311.72M | -19.0% | -27.6% |
| March 31, 2024 | $430.59M | +14.7% | +6.8% |
| December 31, 2023 | $403.34M | +7.5% | +3.6% |
| September 30, 2023 | $389.44M | +3.6% | +1.1% |
| June 30, 2023 | $385.07M | +0.4% | +2.5% |
| March 31, 2023 | $375.51M | +78.8% | +0.1% |
| December 31, 2022 | $375.12M | +83.8% | -0.2% |
| September 30, 2022 | $376.06M | +88.2% | -2.0% |
- Roivant Sciences Ltd. showed an increase of +14.7% in Long-Term Debt compared to the prior fiscal year.
- Over the 2021–2024 period, Roivant Sciences Ltd.’s long-term debt has grown by 152.9% (from $170.28 million to $430.59 million).
- The most recent figure is from Roivant Sciences Ltd.’s fiscal year 2023 report (Form 10-K), filed with the SEC on May 30, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: